AI Engines For more Details: Perplexity Kagi Labs You
Antiparasitic Effects: Fenbendazole is highly effective against a wide range of parasitic infections in animals, including nematodes (roundworms), cestodes (tapeworms), and trematodes (flukes). It works by disrupting the microtubule structure in the parasites, leading to paralysis and death.
Treatment of Intestinal Parasites: Fenbendazole is commonly used to treat gastrointestinal parasites such as roundworms, hookworms, whipworms, and tapeworms in dogs, cats, horses, livestock, and other animals. It helps eliminate the parasites from the intestines, thereby reducing symptoms such as diarrhea, vomiting, weight loss, and abdominal discomfort.
Liver Fluke Infections: Fenbendazole is effective against liver fluke infections, including Fasciola hepatica and Fasciola gigantica, which can affect livestock such as cattle, sheep, and goats. By killing the immature and adult flukes, fenbendazole helps control the spread of these parasitic infections and prevent liver damage in animals.
Lungworm Infections: Fenbendazole is also used to treat lungworm infections in animals, including Metastrongylus spp. in pigs and Dictyocaulus spp. in cattle, sheep, and goats. It helps eliminate the lungworm larvae and adults from the respiratory tract, reducing respiratory symptoms and improving lung function.
Protozoal Infections: In addition to parasitic worms, fenbendazole may have activity against certain protozoal infections in animals, although its efficacy varies depending on the specific parasite species. It is sometimes used off-label for the treatment of protozoal infections such as Giardia and coccidiosis in animals.
Potential Anticancer Effects: There is growing interest in the potential anticancer effects of fenbendazole in humans. Some studies and anecdotal reports suggest that fenbendazole, when used in combination with other drugs or supplements, may inhibit cancer cell growth, induce apoptosis (cell death), and suppress tumor progression. However, more research is needed to fully understand its mechanisms of action and efficacy in cancer treatment.
Safety Considerations: Fenbendazole is generally well-tolerated in animals when used at recommended doses. However, adverse effects such as vomiting, diarrhea, lethargy, and allergic reactions may occur in some cases. It is important to follow dosage instructions carefully and consult a veterinarian before administering fenbendazole to animals, especially pregnant or lactating animals and those with pre-existing health conditions.
Drug Interactions: Fenbendazole may interact with certain medications or supplements in animals, potentially affecting their efficacy or safety. It is important to inform the veterinarian about all medications, supplements, and health conditions of the animal before starting fenbendazole treatment.
Resistance: Prolonged or repeated use of fenbendazole in animals may lead to the development of drug-resistant parasites. To minimize the risk of resistance, fenbendazole should be used judiciously and as part of a comprehensive parasite control program that includes proper hygiene, sanitation, and rotation of anthelmintic drugs.
Rank | Probiotic | Impact |
---|---|---|
species | Akkermansia muciniphila | Reduces |
species | Bifidobacterium adolescentis | Reduces |
species | Bifidobacterium longum | Reduces |
species | Escherichia coli | Reduces |
species | Lactobacillus acidophilus | Reduces |
species | Lactobacillus crispatus | Reduces |
species | Lactobacillus gasseri | Reduces |
species | Lactobacillus helveticus | Reduces |
species | Lactobacillus jensenii | Reduces |
species | Lactobacillus johnsonii | Reduces |
species | Lactobacillus kefiranofaciens | Reduces |
subspecies | Bifidobacterium longum subsp. infantis | Reduces |
subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Acne | 1.1 | -1.1 | |
ADHD | 2.1 | 0.9 | 1.33 |
Age-Related Macular Degeneration and Glaucoma | 0.7 | 0.1 | 6 |
Allergic Rhinitis (Hay Fever) | 0.8 | 1.6 | -1 |
Allergies | 2.8 | 2.1 | 0.33 |
Allergy to milk products | 1.3 | 0.2 | 5.5 |
Alopecia (Hair Loss) | 0.9 | 0.9 | |
Alzheimer's disease | 3 | 5.4 | -0.8 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 2.8 | 0.5 | 4.6 |
Ankylosing spondylitis | 2.2 | 1.6 | 0.38 |
Anorexia Nervosa | 0.6 | 2 | -2.33 |
Antiphospholipid syndrome (APS) | 2.1 | 2.1 | |
Asthma | 0.9 | 1.6 | -0.78 |
Atherosclerosis | 1.1 | 2.2 | -1 |
Atrial fibrillation | 2.5 | 0.5 | 4 |
Autism | 7.2 | 6.5 | 0.11 |
Barrett esophagus cancer | 0.3 | -0.3 | |
benign prostatic hyperplasia | 0 | 0 | |
Bipolar Disorder | 1 | 0.8 | 0.25 |
Brain Trauma | 0.1 | 1.2 | -11 |
Carcinoma | 1.5 | 1.1 | 0.36 |
Celiac Disease | 1.3 | 1.6 | -0.23 |
Cerebral Palsy | 1.1 | 1.2 | -0.09 |
Chronic Fatigue Syndrome | 1.7 | 3.9 | -1.29 |
Chronic Kidney Disease | 1.5 | 1.7 | -0.13 |
Chronic Lyme | 0.7 | -0.7 | |
Chronic Obstructive Pulmonary Disease (COPD) | 1.4 | 1 | 0.4 |
Chronic Urticaria (Hives) | 1.5 | 1.1 | 0.36 |
Coagulation / Micro clot triggering bacteria | 0.5 | 1.3 | -1.6 |
Colorectal Cancer | 2.6 | 0.2 | 12 |
Constipation | 0.7 | 1.2 | -0.71 |
Coronary artery disease | 0.1 | 0.8 | -7 |
COVID-19 | 6.4 | 9.8 | -0.53 |
Crohn's Disease | 4.4 | 4 | 0.1 |
cystic fibrosis | 0.6 | 0.7 | -0.17 |
deep vein thrombosis | 0.1 | 0.8 | -7 |
Depression | 6.5 | 6.2 | 0.05 |
Dermatomyositis | 0.3 | 0.1 | 2 |
Eczema | 0.1 | 2.5 | -24 |
Endometriosis | 2.2 | 1.6 | 0.38 |
Epilepsy | 2.3 | 3.2 | -0.39 |
Fibromyalgia | 1.8 | 2 | -0.11 |
Functional constipation / chronic idiopathic constipation | 3.1 | 3.9 | -0.26 |
gallstone disease (gsd) | 1.6 | 0.6 | 1.67 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.8 | 1.4 | -0.75 |
Generalized anxiety disorder | 0.6 | 1 | -0.67 |
giant cell arteritis | 0.4 | -0.4 | |
Glioblastoma | 0.3 | -0.3 | |
Gout | 0.3 | -0.3 | |
Graves' disease | 1.7 | 1.2 | 0.42 |
Halitosis | 0.2 | 0.3 | -0.5 |
Hashimoto's thyroiditis | 2.7 | 0.5 | 4.4 |
Hidradenitis Suppurativa | 0.3 | 0.3 | |
Histamine Issues,Mast Cell Issue, DAO Insufficiency | 1.9 | 0.9 | 1.11 |
hypercholesterolemia (High Cholesterol) | 0.4 | 0.5 | -0.25 |
hyperglycemia | 0 | 2.1 | 0 |
Hyperlipidemia (High Blood Fats) | 0.8 | 1.6 | -1 |
hypersomnia | 0.7 | -0.7 | |
hypertension (High Blood Pressure | 1.9 | 3.3 | -0.74 |
Hypothyroidism | 0.6 | 1.4 | -1.33 |
Hypoxia | 1 | 1 | |
IgA nephropathy (IgAN) | 2.7 | -2.7 | |
Inflammatory Bowel Disease | 3.8 | 6.2 | -0.63 |
Insomnia | 2.3 | 0.9 | 1.56 |
Intelligence | 0.8 | 0.1 | 7 |
Intracranial aneurysms | 0.8 | 0.5 | 0.6 |
Irritable Bowel Syndrome | 4.3 | 3.8 | 0.13 |
Juvenile idiopathic arthritis | 0.5 | 0.5 | |
Liver Cirrhosis | 3.3 | 2.7 | 0.22 |
Long COVID | 5.4 | 6 | -0.11 |
Low bone mineral density | 1 | -1 | |
Lung Cancer | 0.2 | 1.2 | -5 |
ME/CFS with IBS | 0.7 | 2.2 | -2.14 |
ME/CFS without IBS | 1.2 | 1.1 | 0.09 |
Menopause | 0.5 | 0.5 | |
Metabolic Syndrome | 5 | 5.7 | -0.14 |
Mood Disorders | 8.4 | 6.3 | 0.33 |
multiple chemical sensitivity [MCS] | 2 | 0.5 | 3 |
Multiple Sclerosis | 4.7 | 5.3 | -0.13 |
Multiple system atrophy (MSA) | 1.4 | 0.6 | 1.33 |
Neuropathy (all types) | 1.5 | 0.6 | 1.5 |
neuropsychiatric disorders (PANDAS, PANS) | 0.1 | 0.1 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 2.3 | 3.3 | -0.43 |
NonCeliac Gluten Sensitivity | 0.1 | -0.1 | |
Obesity | 6.2 | 3 | 1.07 |
obsessive-compulsive disorder | 3 | 3.4 | -0.13 |
Osteoarthritis | 1 | 1 | |
Osteoporosis | 1.2 | 1.6 | -0.33 |
pancreatic cancer | 0.3 | 0.3 | |
Parkinson's Disease | 2.4 | 5.3 | -1.21 |
Polycystic ovary syndrome | 2.1 | 1.3 | 0.62 |
Postural orthostatic tachycardia syndrome | 0.4 | 0.3 | 0.33 |
Premenstrual dysphoric disorder | 0.6 | 0.1 | 5 |
primary biliary cholangitis | 0.4 | 0.1 | 3 |
Psoriasis | 4.5 | 1.9 | 1.37 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 4.9 | 3.1 | 0.58 |
Rosacea | 1.8 | 1.4 | 0.29 |
Schizophrenia | 4.6 | 2.5 | 0.84 |
scoliosis | 0.3 | 0.5 | -0.67 |
Sjögren syndrome | 1.2 | 2.3 | -0.92 |
Sleep Apnea | 0.8 | 2.2 | -1.75 |
Small Intestinal Bacterial Overgrowth (SIBO) | 0.3 | 0.1 | 2 |
Stress / posttraumatic stress disorder | 2.9 | 2.4 | 0.21 |
Systemic Lupus Erythematosus | 3.1 | 2.8 | 0.11 |
Tic Disorder | 0.3 | 0.4 | -0.33 |
Tourette syndrome | 0.2 | 0.7 | -2.5 |
Type 1 Diabetes | 2.4 | 3.2 | -0.33 |
Type 2 Diabetes | 4.9 | 6.1 | -0.24 |
Ulcerative colitis | 3.8 | 3.1 | 0.23 |
Unhealthy Ageing | 3.2 | 1.5 | 1.13 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.